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ORIGINAL INVESTIGATION Open Access
Protection of the heart by treatment with a
divalent-copper-selective chelator reveals a novel
mechanism underlying cardiomyopathy in
diabetic rats
Lin Zhang1,2, Marie-Louise Ward2†, Anthony RJ Phillips1,3, Shaoping Zhang1, John Kennedy4, Bernard Barry4,
Mark B Cannell2,7 and Garth JS Cooper1,5,6*†
Abstract
Background: Intracellular calcium (Ca2+) coordinates the cardiac contraction cycle and is dysregulated in diabetic
cardiomyopathy. Treatment with triethylenetetramine (TETA), a divalent-copper-selective chelator, improves cardiac
structure and function in patients and rats with diabetic cardiomyopathy, but the molecular basis of this action is
uncertain. Here, we used TETA to probe potential linkages between left-ventricular (LV) copper and Ca2+
homeostasis, and cardiac function and structure in diabetic cardiomyopathy.
Methods: We treated streptozotocin-diabetic rats with a TETA-dosage known to ameliorate LV hypertrophy in
patients with diabetic cardiomyopathy. Drug treatment was begun either one (preventative protocol) or eight
(restorative protocol) weeks after diabetes induction and continued thereafter for seven or eight weeks, respectively.
Total copper content of the LV wall was determined, and simultaneous measurements of intracellular calcium
concentrations and isometric contraction were made in LV trabeculae isolated from control, diabetic and
TETA-treated diabetic rats.
Results: Total myocardial copper levels became deficient in untreated diabetes but were normalized by
TETA-treatment. Cardiac contractility was markedly depressed by diabetes but TETA prevented this effect. Neither
diabetes nor TETA exerted significant effects on peak or resting [Ca2+]i. However, diabetic rats showed extensive
cardiac remodelling and decreased myofibrillar calcium sensitivity, consistent with observed increases in
phosphorylation of troponin I, whereas these changes were all prevented by TETA.
Conclusions: Diabetes causes cardiomyopathy through a copper-mediated mechanism that incorporates
myocardial copper deficiency, whereas TETA treatment prevents this response and maintains the integrity of cardiac
structure and myofibrillar calcium sensitivity. Altered calcium homeostasis may not be the primary defect in diabetic
cardiomyopathy. Rather, a newly-described copper-mediated mechanism may cause this disease.
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Background
Cardiovascular disease (CVD) is the main cause of mor-
tality in diabetic patients, in whom it is frequently ac-
companied by heart failure [1]. About three-quarters of
the CVD risk in diabetes may be attributable to hyper-
tension [2]. Other significant contributors to risk include
obesity, atherosclerosis, dyslipidaemia, endothelial dysfunc-
tion, defective platelet function, coagulation abnormalities,
and diabetic cardiomyopathy [2]. The latter condition is
considered to be a diabetes-specific cardiomyopathy, which
is independent of macrovascular and microvascular disease
and which contributes substantively to morbidity and
mortality [2-4].
Effective treatments for established heart failure in
diabetes are limited [4,5] and its prognosis is particu-
larly poor in patients with type-2 diabetes (T2D) [6].
Elevated risk persists despite best available treatments
with existing classes of medications, so new and improved
therapeutic approaches for heart failure in diabetes are
required.
Copper is an essential trace element that plays key roles
in many vital copper enzymes, e.g. cytochrome c oxidase,
caeruloplasmin, copper/zinc superoxide dismutase (SOD1),
and lysyl oxidase [7]. Free divalent copper, Cu(II), is the
most redox-active metal ion in mammalian tissues and ex-
cess can cause tissue damage by generating highly-reactive
hydroxyl radicals [8], which inactivate essential enzymes
and cause lipid peroxidation and DNA damage, thereby
disrupting cell metabolism [9,10].
Insufficient dietary copper intake can cause systemic
copper deficiency, myocardial copper deficiency, hyper-
trophic cardiomyopathy, and heart failure [11-14], all of
which are reversible by restoration of normal copper in-
take [15]. Moreover, there is evidence that dietary copper
supplementation reversed hypertrophic cardiomyopathy
induced by chronic pressure overload in mice consuming
a normal-copper diet; in that study, LV copper levels fell
by ~20% as a result of the pressure overload [16], but
systemic copper balance was not reported.
Copper accumulation in excess of bodily requirements is
also cytotoxic [17,18]. Altered tissue copper levels have
sometimes been reported to accompany diabetes in patients
or animal models [19,20]. We have shown, however, in a
phase-2 trial that employed a balance study, that T2D pa-
tients acquire substantive copper overload, and that they do
not demonstrate systemic signs of copper deficiency. Copper
regulation in diabetic patients is thus clearly differentiated
from the copper deficiency states that occur in animals and,
rarely, in patients [21,22]. The significance of dysregulated
copper in diabetes-evoked heart disease was substantively
strengthened when we showed that the Cu(II)-selective
chelator, TETA can restore cardiac structure and function in
diabetic patients and animals, without concomitant lowering
of blood glucose or systemic blood pressure [23,24].
T2D patients acquire a hyperglycaemia-driven patho-
genic abnormality of copper homeostasis that is revers-
ible by TETA-treatment [25], which also restores LV
mass in patients with LV hypertrophy (LVH) [24]. TETA
is a highly-selective divalent copper chelator [25,26],
which is used as a second-line treatment for Wilson’s
disease [27]. In rats used as a model of diabetic cardio-
myopathy, TETA causes cardiac regeneration [23], rever-
sal of LV dysfunction [28], and improved antioxidant
defences [23,29]. In aggregate, these findings provide
substantive support for the idea that defective copper
regulation plays a key role in the pathogenesis of cardio-
myopathy and LV dysfunction in diabetes [22]. However,
the molecular basis for this linkage remains uncertain,
and motivated the current study. The evidence linking
defective copper regulation to the pathogenesis of the
diabetic complications in the heart, kidneys, arteries and
nerves has recently been reviewed [21,22].
Defects in intracellular Ca2+ homeostasis have been
implicated in the impaired mechanical performance of
the diabetic heart [4,30-32] but there is no current con-
sensus from published studies, where resting Ca2+ has
been reportedly decreased [33-35], increased [36,37], or
unchanged [38,39]. Similarly, the amplitude of the Ca2+
transient has also been reported as decreased [35,40-42],
increased [36], or unchanged [43,44]. Therefore, we re-
examined the changes in Ca2+ homeostasis underlying
diabetic cardiomyopathy in the current study. We also
determined whether TETA exerts its inotropic effects by
modifying intracellular Ca2+ homeostasis, since copper
dysregulation can generate reactive oxidative species
and cause defects in anti-oxidant defences which could
further accentuate abnormalities in intracellular Ca2+
regulation [45,46].
Here we have tested the hypothesis in rats used as a
model of the diabetic complications that diabetes might
cause linked abnormalities of copper and calcium homeo-
stasis, which could interact to yield cardiomyopathy and
LV dysfunction.
Methods
Animals This study was approved by the University of
Auckland Animal Ethics Committee and performed
according to the Guide for the Care and Use of Labora-
tory Animals [47] and the ARRIVE guidelines for the
reporting of animal research [48].
Reagents All chemical reagents were obtained from
Sigma and were of analytical grade or better, unless
otherwise stated.
Induction and verification of diabetes in rats Diabetes
was induced in adult male Wistar rats (200–250 g body-
wt; 6–7 weeks of age) by a single intravenous injection
of STZ (60 mg/kg body-wt dissolved in 0.9% saline) as
described [32]; control rats received 0.9% saline only.
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Diabetes was diagnosed by demonstration of sequential
tail-vein blood glucose concentrations >11 mmol/L [23].
TETA disuccinate (CarboGen, Switzerland; 30 mg/day-rat)
in the drinking water (18 MΩ; MilliQ, Millipore, Billerica,
MA) [49] was begun either one week after injection and
continued for a further 7 weeks (preventative protocol,
[32]), or 8 weeks after injection and continued for a further
8 weeks (restorative protocol [23]). Throughout the study,
animals were housed (in pairs) in a temperature-controlled
unit with a fixed 12-hr light/dark cycle, and received
ad libitum access to food and water.
Rationale for choice of drug dosage We based the choice of
TETA dosage used here on those employed in known
clinical applications of TETA (TETA dihydrochloride or
trientine) in the treatment of Wilson’s disease, and for the
experimental therapy of diabetes. Dosages employed for the
treatment of Wilson’s disease in adults typically vary from
750–2000 mg/day (equivalent to ~10.7-28.6 mg/kg-day in
70-kg adults) [50]. Here, we administered TETA disuccinate
(a new salt form with improved stability characteristics [49])
in the drinking water to diabetic rats at 30 mg/day (equiva-
lent to ~17 mg/day-rat or ~68 mg/kg-day of trientine in
250-g rats). This dosage is supported by our published dose-
rising phase-1 clinical trial, where we showed that dosages of
1200 and 3600 mg/day (equivalent to ~17 and 51 mg/kg-day
in 70-kg adults) were effective and well tolerated in healthy
human volunteers [51] and also by our published phase-2
trial where 1200 mg/day of trientine (~17 mg/kg-day
in 70-kg adults) administered for 12 months markedly
improved LV mass in T2D patients with LVH [24].
Measurement of myocardial copper levels was performed
by applying particle-induced X-ray emission spectroscopy
(PIXE) with Rutherford backscattering spectrometry (RBS)
in freeze-dried sections of ex vivo LV myocardium [52]
according to established methods [53]. The calibration,
measurements and limits of detection were based on the
areas of the Kα x-ray peaks as assessed by the software
package GUPIX Elemental, and concentrations were
extracted from PIXE spectra using GUPIX software
(gupix@listserv.uoguelph.ca).
Force and [Ca2+]i in left ventricular trabeculae were
measured as previously described [54]. Briefly, unbranched
and cylindrical trabeculae were dissected free from the
underlying LV tissue and mounted on a force transducer
(AE801, SensorOne, Sausalito CA) on the stage of an
inverted microscopy (Nikon Diaphot 300, Japan). The tra-
beculae were perfused with Krebs-Henseleit (KH) solution
containing (in mmol/L): NaCl, 118; KCl, 4.75; KH2PO4,
1.18; MgSO4, 1.18; NaHCO3, 24.8; and D-glucose, 10; with
BDM, 20; CaCl2, 0.5; gassed with O2:CO2 95:5 [vol/vol].
Once the trabeculae were producing stable stimulus-
evoked twitches, they were loaded with the fluorescent
Ca2+ indicator fura-2/AM (10 μmol/L, 2-hr; Invitrogen,
Carlsbad, CA). Force and [Ca2+]i were then measured
simultaneously at a fixed sarcomere length (2.1-2.2 μm),
either at 37°C, 5-Hz, and 1.5 mmol/L [Ca2+]o, or other
experimental conditions. The ratio of the emitted fluores-
cence at the two excitation wavelengths (340/380 ratio) of
fura-2 was obtained (Cairn Research, Faversham, Kent,
UK) as a measurement of [Ca2+]i. The force measure-
ments were normalized by the trabecular cross-sectional
area and expressed as stress (mN/mm2).
The steady-state force-[Ca2+]i relationship was evaluated
in LV trabeculae treated with 5 μmol/L of ryanodine, a
plant alkaloid considered to block ryanodine receptor
channels to generate a long-lived subconductance
(half-open) state [55] and eventually to deplete the
sarcoplasmic-reticular calcium stores. The drug effect
reached steady state after 30-min exposure, whereupon
fused tetani could be reliably elicited by rapid stimula-
tion (12 Hz) for 6 s at a series of [Ca2+]o values from
0.5 mmol/L to the concentration where the maximum
force was obtained. Tetanus at different [Ca2+]o was
separated by a “resting” period of 2 min. To avoid pre-
cipitation at high Ca2+ concentrations, solutions used in
these experiments were switched to a phosphate-free
composition including (in mmol/L): NaCl, 108; KCl, 5;
MgCl2, 1; HEPES, 5; NaCH2COOH, 20; and D-glucose,
10. Calibration in terms of absolute values of [Ca2+]i
and data analysis were performed following published
procedures [32,54].
Measurement of caffeine-induced Ca2+ transients in
isolated cardiomyocytes LV cardiomyocytes were isolated
by enzymatic digestion with 1 mg/ml collagenase Type-II
(Worthington, NJ, USA) and 0.1 mg/ml proteinase type-
XXIV (Sigma, MO, USA) as previously described [56].
The yield of the isolation was usually around ~80%.
Cardiomyoctes were loaded with fura-2/AM (5 μmol/L,
10 min; Invitrogen). Rod-shaped quiescent cardiomyocytes
with sharp edges and clear striations were used in the
investigation. Caffeine-induced Ca2+ transients were
recorded from cardiomyocytes isolated from each
group of rats, which were exposed to a series of solu-
tion changes. Firstly, cells were stimulated at 1 Hz in
normal Tyrode’s solution (in mmol/L): HEPES, 10;
NaCl, 143; KCl, 5.4; MgCl2, 0.5; glucose, 10; taurine,
20; and CaCl2, 1.5; pH 7.4 finally adjusted with NaOH.
Then, following 30-s perfusion with Tyrode’s solution
with 0 mmol/L [Ca2+]o and without stimulation,
10 mmol/L caffeine was added (to functionally elimin-
ate Ca2+ storage in the SR), and Ca2+ transients were
recorded. After the [Ca2+]i had decreased to the rest-
ing level, cells were perfused with Tyrode’s solution in-
corporating 1.5 mmol/L [Ca2+]o and stimulated at 1 Hz
(to restore the SR Ca2+) followed by a further series of so-
lution changes in the following order: 0 mmol/L [Ca2+]o,
30 s; and then 10 mmol/L caffeine with 0 mmol/L [Na+]o
and 10 mmol/L [Ni2+]o (to eliminate both the SR Ca
2+
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store and sarcolemmal Ca2+ extrusion via the Na/Ca
exchanger (NCX). Ca2+ transients were continuously
recorded.
Western Blotting was performed with proteins extracted
from LV tissue as described [32]. Briefly, frozen LV tissue
was homogenized in ice-cold lysis buffer (50 mmol/l Tris–
HCl, pH 8; 150 mmol/l NaCl; 1% NP-40; 0.5% sodium
deoxycholate; and 0.1% sodium dodecylsulphate) with a
proteinase inhibitor mixture and a phosphatase inhibitor
mixture (Roche, Indianapolis, IN), and then centrifuged at
13,000 g for 1 h at 4°C. Protein concentration in the
supernatant was determined with a bicinchoninic acid
protein assay (Pierce, Rockford, IL). Western blots were
performed by using a rabbit anti-NCX antibody (Ab,
1:500, Swiss Antibodies, Swant, Switzerland), a mouse
anti-SERCA2a antibody (1:1000, Affinity BioReagents,
Golden, CO, USA), a mouse anti-TnT antibody (1:1000,
Abcam, Cambridge, UK), and a mouse anti-TnI antibody
(1:1000, Abcam). Specific signals were detected using anti-
rabbit or anti-mouse IgG-horseradish peroxidase conju-
gate and ECL-Plus Western Blotting Detection Reagents
(GE Healthcare, Little Chalfont, Buckinghamshire, UK)
according to the manufacturer's instructions. An LAS
3000 image reader (Fuji Photo Film Co. Ltd, Tokyo, Japan)
was used to detect signals and take images of the mem-
branes. Phosphoproteins were detected by using Pro-Q
Diamond phosphoprotein gel-stain followed by SYPRO®
Ruby total protein gel-stain (Invitrogen) and signals were
detected by a Pharos FX™ Plus Molecular Imager (BioRad,
CA). Afterwards, all images were analysed using Multi
Gauge analysis software (Fuji Photo Film).
Immunohistochemistry of LV free wall was performed
as described [32]. Briefly, sectioned cardiac tissues (30 μm)
were immunolabelled with rabbit anti-rat type-I or type-III
collagen antibody (1:100 in 5% goat serum/1% BSA/PBS;
Chemicon, Boronia, Australia), and then with secondary
antibody (1:200) (Alexa Fluor 488 goat anti-rabbit Ab;
Invitrogen) and phalloidin-rhodamine (1:100, Invitrogen).
Slides were imaged with a confocal microscope (Zeiss
LSM410). F-actin and collagen types-I and -III were quan-
tified using a custom-written IDL analysis program based
on signal-thresholding.
Statistical analysis Data are expressed as mean ± SE.
Differences between means were analysed by using ana-
lysis of variance (ANOVA) with appropriate post-hoc
tests. Statistical difference was considered significant at
P < 0.05. Normality and equality of variance of samples
were tested by applying the Shapiro-Wilk test or Spear-
man rank correlation, respectively. If either of these two
tests failed, then Kruskal-Wallis one-way ANOVA with
Dunn’s multiple comparisons test was used for the
statistical analysis. Otherwise, one-way ANOVA with the
post-hoc Holm-Sidak method or Tukey’s post-hoc test
were used as appropriate.
Results
Metabolic responses to drug treatment TETA had no
effect on the elevated blood glucose levels in diabetic
rats, although it significantly increased the body-weight
of diabetic rats in the latter stages of preventative treat-
ment (Week 8; P = 0.02, Table 1); these findings could
imply the occurrence of a systemic/metabolic improve-
ment in TETA-treated animals without improved
glycaemic regulation.
TETA-treatment restored total copper content in LV
myocardium of diabetic rats After 16 weeks (restorative
protocol as per Methods [23]), the total copper content
of the LV myocardium was much lower in diabetic ani-
mals than in controls (diabetic: 29 ± 2 μg/g dry LV tissue,
n = 7; control: 50 ± 6 μg/g, n = 7, P = 0.030), whereas in
TETA-treated diabetic animals, total copper was fully
normalized (TETA-treated diabetic: 48 ± 6 μg/g, n = 7,
P = 0.032 vs untreated diabetic).
TETA prevented diabetes-evoked QTc prolongation Un-
treated diabetes caused significant slowing of the heart rate
compared with control values (P < 0.0001), and TETA did
not modify this effect. However, QT intervals corrected for
heart rate (QTC) were prolonged in diabetic rats whereas
Table 1 Descriptive variables on the experimental day (at week 8)
Control Diabetic TETA-treated diabetic P
Body-weight (g) 438 ± 7 (28) 247 ± 8 (28) a 269 ± 5 (26) b, c <0.0001
Heart-weight (g) 1.60 ± 0.07 (24) 1.24 ± 0.06 (24) a 1.25 ± 0.05 (20) c <0.0001
Tibial length (cm) 4.23 ± 0.04 (13) 3.86 ± 0.06 (16) a 3.87 ± 0.06 (20) c <0.0001
Heart weight/Body-weight (x 103) 3.7 ± 0.1 (23) 5.3 ± 0.2 (21) a 5.0 ± 0.2 (20) c <0.0001
Heart weight/ (Tibial length)2 (mg/cm2) 94 ± 4 (13) 90 ± 5 (13) 84 ± 3 (20) 0.23
Blood glucose (mmol/L) 4.7 ± 0.1 (24) 30.8 ± 0.8 (30) a 32.2 ± 0.7 (26) c <0.0001
Heart rate (min-1) 390 ± 9 (11) 311 ± 6 (18) a 315 ± 12 (10) c <0.0001
Corrected QT interval (ms) 177 ± 4 (11) 192 ± 4 (18) a 138 ± 14 (10) b 0.001
Data are means ± SEM. Numbers of animals were as shown in parentheses. P-values are by Kruskal-Wallis one-way ANOVA with Dunn’s multiple-comparisons test
or one-way ANOVA with the Holm-Sidak method as appropriate; a, b, c, significant differences: a, Control vs Diabetic groups; b, Diabetic vs TETA-treated diabetic; c,
Control vs TETA-treated Diabetic.
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TETA prevented the development of QTC prolongation
(Table 1). By contrast, TETA treatment did not modify QTc
values in non-diabetic rats (results not shown).
These data are consistent with the idea that TETA-
mediated prevention of QTc prolongation resulted from
normalization of myocardial copper regulation, pointing
to the existence of copper-mediated mechanisms that
contribute to QTc regulation.
TETA prevented the diabetes-evoked deterioration of
cardiac contractility Diabetic rats showed depressed peak
stress compared to controls (P = 0.02; Figures 1Bii, 2Aiii)
but this response was prevented by TETA (P = 0.04).
Resting stress was not significantly different between
experimental groups (Figures 1Bii, 2Aiv). Neither dia-
betic status nor TETA exerted significant effects on
the levels of peak/or resting [Ca2+]i (Figures 1Bi, 2Ai, ii).
Figure 1 Isometric force and [Ca2+]i measured from LV trabeculae. Isometric force and [Ca
2+]i were measured simultaneously in LV
trabeculae at 37°C, 5 Hz stimulation frequency and 1.5 mmol/L [Ca2+]o, conditions that are close to physiological. (A) Exemplary traces of Ca
2+
transients (fura-2/AM 340/380 ratio) and corresponding isometric stress (force normalized to the corresponding muscle’s cross-sectional area)
averaged over a number of cardiac cycles in representative trabeculae from the 3 experimental groups, which typify those used for data analysis.
Inserted figures are corresponding raw traces of Ca2+ transients and corresponding isometric stress. (B) Averaged values from 7 trabeculae in
each experimental group for (i) the Ca2+ transient, (ii) isometric stress and (iii) phase plots of Ca2+ transients and corresponding isometric stress.
Diabetic rats showed decreased responsiveness to Ca2+, as indicated by the rightward shift of the relaxation phase (iii) and TETA-treatment
prevented development of this defect.
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The relaxation-phase of isometric stress plotted against
[Ca2+]i showed a rightward-shift in diabetic rats, consistent
with decreased myofibrillar Ca2+ sensitivity [57], whereas
this effect was fully prevented by TETA (Figure 1Biii).
Although peak and resting levels of [Ca2+]i were
maintained in all experimental animals, diabetic rats had
a prolonged time-course of their Ca2+ transients (in-
creased time-to-peak [Ca2+]i and time-constant of decay)
compared to controls (both P = 0.02, Figure 2Bi, ii).
Consistently, the time-course of contraction in diabetic
rats was also slower (increased time-to-peak stress and
time-to-90 % relaxation, P = 0.001 and P = 0.025, respect-
ively, Figure 2Biii, iv). Moreover, TETA had no effect on
the prolonged time-course of either the contraction or
the Ca2+ transient in diabetic rats.
Decay of the Ca2+ transient in the rat is dominated by
the rate of Ca2+ uptake by the sarcoplasmic reticulum via
SERCA2a and, to a lesser extent by sarcolemmal Ca2+ ex-
trusion via the Na/Ca exchanger (NCX, ~7-9% of total)
[58]. Caffeine-induced Ca2+ transients were recorded and
analyzed from LV cardiomyocytes to assess the activity
of SERCA2a and NCX in the experimental groups.
10 mmol/L caffeine was used to eliminate the SR stor-
age of Ca2+ during the decay of the Ca2+ transient,
while 10 mmol/L [Ni2+]o and 0 mmol/L [Na
+]o were
used to further eliminate the contribution of NCX to
Figure 2 Depressed cardiac contractility in diabetic rats prevented by TETA-treatment. Depressed cardiac contractility in diabetic rats was
prevented by TETA-treatment, which by contrast did not modify diabetes-induced alterations in [Ca2+]i homeostasis. (A) Diabetic rats showed
unchanged peak (i) and resting (ii) [Ca2+]i values but had concomitantly decreased peak stress (iii) (Diabetic: 10 ± 1 mN/mm
2; Control: 17 ± 2 mN/
mm2, P = 0.02) and unchanged resting stress (iv). TETA-treatment preserved peak stress in diabetic rats (TETA-treated diabetic: 20 ± 4 mN/mm2,
P = 0.04) but did not significantly modify peak or resting [Ca2+]i. (B) The time course of the Ca
2+ transient was prolonged in diabetic rats: (time-
to-peak [Ca2+]i (i); and time constant of decay of the Ca
2+ transient (ii)), as was the time course of isometric stress (time-to-peak stress (iii); and
time-to-90% relaxation (iv)). However, TETA-treatment had no effect on the time course of either variable. (C) The maximum rate of rise in the
Ca2+ transient was unchanged (i) whereas the maximum rate of stress development was decreased in diabetic rats (ii), and this decrease was
prevented by TETA-treatment. C: Control (Open bars, n = 10); D: Diabetic (Solid bars, n = 8); D + T: TETA-treated diabetic (Patterned bars, n = 7).
Data are means ± SEM, one-way ANOVA with application of the post-hoc Holm-Sidak test: * C vs D; ‡ C vs D + T; † D vs D + T; P < 0.05.
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the decay of the Ca2+ transient. Results (Figure 3A)
showed no significant difference in the time-constant
of decay of caffeine-induced Ca2+ transients among
groups in any of the perfusion solutions. In compari-
son with the slower time-constant of decay of normal
Ca2+ transients in diabetic rats, the unaltered caffeine-
induced Ca2+ transients indicate that SERCA2a activity
was down-regulated whereas NCX activity was un-
changed. These findings are consistent with the Western-
blotting study (Figure 3B), in which diabetic rats showed
lower levels of SERCA2a (P = 0.01), whereas NCX was
unaltered. These results could explain the slower decay of
the Ca2+ transient in diabetic trabeculae. TETA had no
significant effect on the expression of these proteins, con-
sistent with the unchanged decay-rate of the Ca2+ transi-
ent in TETA-treated diabetic rats.
The unchanged levels of peak and resting [Ca2+]i
coupled with the slower kinetics of the Ca2+ transient
cannot explain the depressed cardiac contractility in dia-
betic rats [32], since these alterations would favour in-
creased force production, which was not observed here.
We therefore hypothesized that altered [Ca2+]i handling
may not be the primary contributor to diabetes-evoked
cardiac dysfunction, and that diabetic rats may have
intrinsic myocardial defects that contribute to their
depressed cardiac contractility. Our observations invited
further investigation of myofibrillar Ca2+ sensitivity and
cardiac remodelling in diabetic rat hearts.
TETA prevented the development of abnormal myofi-
brillar Ca2+ sensitivity in diabetic hearts The rightward-
shift in the relaxation component of the phase-plot of
isometric stress and [Ca2+]i in diabetic rats (Figure 1Biii),
is consistent with decreased myofibrillar Ca2+ sensitivity.
TETA prevented this rightward-shift, suggesting that
myofibrillar Ca2+ sensitivity was preserved in the drug-
treated diabetic animals, contributing to their normal
cardiac contractility. However, the rapid change in the
Ca2+ transient during a normal twitch does not favour
full development of the interaction between myofila-
ments and [Ca2+]i. We therefore investigated the steady-
state force-[Ca2+]i relationship to assess the role of Ca
2+
in modulating force production under these conditions.
Trabeculae were treated with 5 μmol/L ryanodine and
high stimulation-frequency (12 Hz, 6 s) to induce cardiac
tetanus for investigation of the steady-state force-[Ca2+]i
relationship (Figure 4A) [59]. During each tetanus, stress
plateaued 3–4 s after the onset of stimulation, while
[Ca2+]i increased throughout. Tetanized stress and [Ca
2+]i
increased with increasing [Ca2+]o until maximum stress
was reached: that is, increase in stress ceased even if
[Ca2+]i continued to increase. Measurement of stress
and [Ca2+]i were obtained 4 s after stimulation onset
for each [Ca2+]o level and values were fitted with the
Hill equation (see Figure 4B, pooled data summarized
in Table 2). Diabetic rats showed depression of max-
imum Ca2+-activated contractility to ~47% of control
values (P = 0.008) whereas TETA-treatment preserved
the maximum contractility in treated-diabetic animals
(P = 0.03). Untreated-diabetic rats also showed increased
K1/2 (the value of [Ca
2+]i when half the maximum stress
was reached), consistent with decreased myofibrillar Ca2+
sensitivity (P = 0.012). TETA prevented this alteration of
K1/2, suggesting that drug-treated diabetic rats have nor-
mal myofibrillar Ca2+ sensitivity compared to untreated
ones (P = 0.05). Furthermore, the phase-plot between
[Ca2+]i and tetanus at 20 mmol/L [Ca
2+]o from a number
of trabeculae in each experimental group (Figure 4D)
demonstrated a right-shifted relaxation phase in diabetic
rats consistent with decreased myofibrillar Ca2+ sensitivity,
which was prevented by TETA.
In addition to the conventional method of obtaining in-
dividual data points for [Ca2+]i and stress at each [Ca
2+]o
value to fit by the Hill equation, we analyzed phase-plots
between [Ca2+]i and tetanic force corresponding to a
series of [Ca2+]o levels (Figure 4C). Values obtained during
the rising phase of the phase-plots represented the max-
imum force produced by a trabecula at a particular [Ca2+]i
value. Comparisons between the slopes of the initial por-
tion of the phase-plots from the three different experi-
mental groups provides an indication of the dependence
of cardiac contractility on [Ca2+]i. Diabetic rats had de-
creased slopes compared to controls (diabetic 0.7 ± 0.2,
n = 7 vs control 2.2 ± 0.5, n = 9, P = 0.02), and TETA
prevented this reduction (TETA-treated diabetic 5 ± 2.1,
n = 7, P = 0.05). This finding is consistent with that
obtained using the conventional Hill equation fitting
method (Figure 4B, Table 2).
Myofibrillar Ca2+ sensitivity is not only determined by
the binding affinity of Ca2+ to troponin C (TnC) but also
affected by the phosphorylation status of the troponin
complex (comprising TnI, TnT, and tropomyosin), by
the cooperation between the troponin complex and
F-actin, and by force generation via binding of cross-
bridges. Alterations in protein expression of TnT [60]
and TnI [61], or changes in their phosphorylation status
[62] have been reported to occur in diabetic cardiomyop-
athy in association with decreased myofibrillar Ca2+ sensi-
tivity. Here, we found that there were no significant
differences in levels of TnT or TnI between diabetic and
control LV myocardium (Figure 4E). In addition, TETA
had no measurable effects on the expression level of
these proteins in diabetic hearts. However, the propor-
tion of phosphorylated TnI (Figure 5i) was increased in
diabetic myocardium compared with control values
(diabetic vs controls, P < 0.01), which could contribute
to their decreased myofibrillar Ca2+ sensitivity. By con-
trast, TETA treatment maintained the phosphorylation
of TnI at normal levels (diabetic vs TETA-treated
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Figure 3 Alterations in SERCA2a and NCX in LV myocardium. (A) Caffeine-induced Ca2+ transients were recorded from cardiomyocytes
isolated from each group of rats, which were exposed to a series of solution changes as described in methods. (i) shows examples of normalized
caffeine-induced Ca2+ transients from a single cell, with pooled data shown in (ii)&(iii). There was no significant difference in the time-constant of
decay of caffeine-induced Ca2+ transients among groups in either of the caffeine perfusion solutions, indicating no change of NCX activity
among groups. These data suggest that the slower decay of the Ca2+ transient in diabetic rats did not arise from differences in NCX function.
Consistently, a western blotting study (B) showed no significant change in NCX levels (molecular weight 120 kDa, n = 8 in each group) among
groups, but decreased expression of SERCA2a (molecular weight 110 kDa, n = 7 in each group) in diabetic rats. TETA had no effect on levels of
either transporter. C: Control (Open bars); D: Diabetic (Solid bars); D + T: TETA-treated diabetic (Patterned bars). Data are means ± SEM, one-way
Kruskal-Wallis ANOVA with post-hoc application of Dunn’s Multiple Comparisons test (P = 0.0007): * C vs D, P < 0.05; † C vs D + T, P < 0.05.
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diabetic, P < 0.05), therefore preventing the reduction
of the myofibrillar Ca2+ sensitivity. In addition, neither
diabetes nor TETA treatment modified the phosphor-
ylation of TnT (Figure 5ii).
TETA prevented structural deterioration of cardiac
muscle Diabetic rats showed decreased LV free-wall
thickness and increased intramural collagen labelling
compared to control animals (Figure 6A, diabetic: 3.3 ±
0.4 mm, n = 8 vs control: 5.3 ± 0.3 mm, n = 8, P = 0.002).
Quantification showed an average increase of 14% in
type-I collagen per cross-sectional area (P = 0.003) in
diabetic hearts, without significant change in type-III
collagen area (Figure 7C). Diabetic hearts also showed
disorganized F-actin (Figure 6Bii), with significantly
Figure 4 The steady-state force-[Ca2+]i relationship and expression of TnT & TnI in LV myocardium. (A) Representative traces of [Ca
2+]i
and stress during tetanic stimulation of a trabecula from a diabetic rat (at [Ca2+]o: 0.5, 5, 15 and 30 mmol/L); the solid arrows indicate where
stimulation started and ended; the dashed arrows indicate that the resting [Ca2+]i and the corresponding resting stress at 30 mmol/L [Ca
2+]o
were comparable to the tetanized [Ca2+]i and its corresponding stress at 5 mmol/L [Ca
2+]o. (B) The corresponding data obtained 4 s after
commencing tetanic stimulation from this trabecula were fitted to the Hill equation as shown. (C) The rising aspects of the phase plots of [Ca2+]i
and tetanus at different [Ca2+]o values from the same trabecula are shown (irregular grey lines), where the data used for fitting to the Hill
equation (as in B) have been superimposed (black squares). (D) Averaged relaxation phase plots of [Ca2+]i and tetanus at [Ca
2+]o 20 mmol/L from
numbers of trabeculae in each experimental groups (Control: black line, n = 9; Diabetic: red line, n = 7; TETA-treated diabetic: blue line, n = 7).
Diabetic rats showed a rightward shift of the relaxation phase, consistent with decreased myofibrillar Ca2+ sensitivity whereas TETA-treatment
preserved the Ca2+ sensitivity in diabetic hearts. (E) Expression of TnT (upper left panel shows representative western blots of three animals from
each group; box and whisker plots (median, range) below show normalized densitometry of both TnT bands (i) & ratios of the two TnT bands (ii)
at molecular weights in the range of 40–42.5 kDa, n = 5 in each group); and TnI (right panel; iii, molecular weight 28 kDa, n = 6 in each group) in
LV tissue from the three experimental groups; these showed no significant between-group differences. C: Control (Open bars); D: Diabetic (Solid
bars); D + T: TETA-treated diabetic (Patterned bars). Significance was tested by one-way Kruskal-Wallis ANOVA.
Table 2 Values obtained by fitting the Hill equation to
the stated number of trabeculae in each group
Control Diabetic TETA-treated
diabetic
Number 9 7 7
Maximum stress (mN/mm2) 38 ± 4 18 ± 4 a 39 ± 8 b
Hill coefficient (N) 6.3 ± 1.2 5.1 ± 0.9 8.4 ± 1.6
K1/2 (nmol/L) 688 ± 60 1018 ± 105
c 799 ± 37
Data are means ± SEM. P-values were determined by Kruskal-Wallis one-way
ANOVA with post-hoc Dunn’s Multiple-Comparisons tests: a, Diabetic vs Control
groups, P = 0.008; b, Diabetic vs TETA-treated diabetic rats, P = 0.03; c, Diabetic
vs Control rats, P = 0.012.
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decreased (by ~8%) content of F-actin (P < 0.0001, Figure 7C).
TETA prevented the increase in type-I collagen labelling
in diabetic hearts (P = 0.008, Figure 7C), and also
prevented the disruption in F-actin to a significant extent
(P < 0.0001, Figures 6Biii, 7C). These responses may
account, at least in part, for TETA’s ability to prevent
cardiac dysfunction.
Discussion
In consideration of the importance of intracellular Ca2+
in the regulation of the cardiac contraction cycle, and re-
ports of altered [Ca2+]i homeostasis in diabetes [30-32],
we have determined whether TETA could exert its ino-
tropic effects through modulation of myocellular [Ca2+]i.
We also sought to understand the relationship between
perturbations in the myocardial homeostasis of calcium
and of copper in diabetes, and the effects of TETA treat-
ment on both.
We report here that diabetes lowered the total copper
content of LV myocardium in rats by ~50% as determined
by PIXE, consistent with a recent finding [63], whereas
TETA-treatment restored the total myocardial copper
content to normal. We also show that TETA treatment
prevented the onset of cardiac dysfunction in diabetic rats
despite their sustained hyperglycaemia (> 30 mmol/L), de-
creased body-weight and increased water consumption
throughout the study, all of which are consistent with
severe diabetes (Table 1).
In addition, TETA prevented the diabetes-evoked pro-
longation of the QTc interval. QTc prolongation may
presage increased risk of macrovascular disease and fatal
cardiac arrhythmias in diabetic patients [64], and also
Figure 5 Gel electrophoresis of LV extracts from treatment groups of rats. Gels were stained with Pro-Q Diamond (for phosphoproteins) and
SYPRO® Ruby (for total protein). Upper panels show representative gels (n = 3/group). Lower panels show graphical representation of the results of
densitometry: (i) Diabetic animals (D, n = 6, solid bars) showed increased proportions of phosphorylated TnI (expected molecular weight, 28 kDa)
compared with controls (C, n = 6, open bars) whereas TETA-treated diabetic animals (DT, n = 6, patterned bars) showed levels comparable to
control values. (ii) Neither diabetes nor TETA treatment modified the phosphorylation of TnT (expected molecular weight, 40–42.5 kDa). Data in
lower panels are means ± SEM analysed by one-way ANOVA (P = 0.005) with post-hoc Tukey’s Multiple Comparisons tests: *, C vs D, P < 0.01; †, D
vs DT, P < 0.05. Abbreviations: TnI, troponin I; TnT, troponin T.
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occurs in animals with cardiomyopathy caused by copper
deficiency [13,65]. The observed correction of the QTc
interval in diabetic cardiomyopathy coincided with
normalization of myocardial copper regulation by TETA,
and could signal improvement in the electrophysiological
and mechanical properties of the heart following treat-
ment. We have previously shown that TETA treatment of
non-diabetic rats, at doses equivalent to those employed in
diabetic animals, had no discernible effect on cardiac struc-
ture or function [23]. Therefore, the effects of TETA treat-
ment in non-diabetic rats were not studied further in the
current work.
Here, diabetic rats showed altered [Ca2+]i regulation as
reflected in the prolonged time-to-peak [Ca2+]i and time-
constant of decay of the Ca2+ transient (Figure 2Bi, ii),
consistent with published reports [30,31]. The measured
decrease in expression of SERCA2a and its activity in
these diabetic rats (Figure 3B) may well explain the slower
decay of the Ca2+ transient. It would be expected to lower
SR Ca2+ uptake and release, thus decreasing the amplitude
of the Ca2+ transient. However, this effect was offset by
either the prolonged action-potential duration (QTc inter-
val) observed in these diabetic rats through increasing the
sarcolemmal Ca2+ influx; or by the increase of Ca2+ influx
via NCX during the diastolic period due to increased
[Na+]i [32]; or both. These ultimately resulted in the
unchanged amplitude of the Ca2+ transient (Figure 2Ai, ii).
Normal amplitude of the Ca2+ transient with slower kinet-
ics would be expected to favour force production, but this
was not the case here. On the contrary, depressed peak
stress was observed in the untreated-diabetic rats. This
finding is consistent with the hypothesis that altered [Ca2+]i
handling may not be the primary contributor to the de-
pressed cardiac contractility in diabetic rats, and that TETA
protects cardiac function by influencing variables other
than [Ca2+]i.
Indeed, diabetic rats displayed decreased myofibrillar
Ca2+ sensitivity (Figures 1Biii, 4D; Table 2), which may
Figure 6 Confocal sections of LV free wall. Confocal microscopy was used to image fluorescent antibody labels to identify type I & type III
collagen, and phalloidin-rhodamine labelled F-actin in sections (30 μm) from the LV free wall. (A) Shows representative LV wall cross-sections (16
х objective) labelled for F-actin (red) and type I collagen (green) in control (i), diabetic (ii) and TETA-treated diabetic rats (iii) (n = 7/group).
Diabetic rats had decreased LV wall thickness and increased collagen labelling compared to controls; TETA-treatment normalized type I collagen
labelling. (B) illustrates representative longitudinal sections of LV tissues (40 х objective, zoom 3) from control (i), diabetic (ii) and TETA-treated
diabetic rats (iii). Diabetic rats displayed disrupted F-actin structure whereas TETA-treatment maintained F-actin integrity.
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partly account for their depressed cardiac contractility,
whereas TETA prevented this decrease from developing.
In our study, we used intact muscle preparations to assess
myofibrillar Ca2+ sensitivity at physiological temperature.
Compared with skinned heart-muscle fibres or cells
[66-69], in which the surface membrane has been perme-
abilized, our preparations kept the intracellular environ-
ment intact, thus avoiding the possibility that myofibrillar
Ca2+ sensitivity was affected by perturbations in the
intracellular environment. For example, disruptions of
physiologically-occurring cytosolic factors such as hydro-
gen and phosphate ion levels would affect the sensitivity
of myofilaments to Ca2+ [68,69].
Our use of intact, ryanodine-treated LV trabeculae
consistently produced tetani at different [Ca2+]o levels
(Figure 4). Upon tetanic stimulation, [Ca2+]i rose steadily
throughout whereas force plateaued and thereafter
remained constant (Figure 4A), indicating that maximal
Ca2+-activated force had been reached. At high levels of
[Ca2+]o, the resting [Ca
2+]i was elevated in comparison
to that at lower [Ca2+]o, suggesting the possibility of in-
creased intracellular [H+]. However, when comparisons
were made between the resting force at high [Ca2+]o and
the peak tetanic force at low [Ca2+]o, they were compar-
able for similar [Ca2+]i. For example, in Figure 4A
(dashed line), the resting force at 30 mmol/L [Ca2+]o was
comparable to the tetanic force at 5 mmol/L [Ca2+]o. This
indicates that high [Ca2+]o evoked either no, or at most
minor changes in intracellular [H+], which would be
unlikely to affect trabecular force production.
Normally, tension development is initiated by Ca2+
binding to TnC, which triggers a series of reversible
interactions and structural changes among the proteins
of the thin filaments (TnI, TnT and Tm), therefore ex-
posing the myosin binding sites on actin to enable cross-
bridge formation. As a result of the cooperative nature
of this process, a decreased propensity of Ca2+ binding
to evoke the conformational changes of these proteins
and cross-bridge formation would eventually affect force
development. Alterations in the relative expression of
TnT isoforms have been demonstrated, coincident with
diminished Ca2+ sensitivity of skinned cardiac-muscle
contractility in diabetic rats [60]. Here, we found that
neither diabetes nor TETA affected cardiac levels of
TnT and its isoforms (Figure 4E). This between-study
difference may well have been caused by different ex-
perimental conditions and the disease stages used in dif-
ferent studies: for example, the animals in the above
study had been diabetic for substantially longer than
ours. Although unchanged expression levels of TnI have
been reported in diabetic hearts with diminished Ca2+
sensitivity [70], consistent with this report (Figure 4E),
others have reported down-regulation of TnI in con-
junction with diminished Ca2+ sensitivity in a cardiac
actomyosin system reconstituted with regulatory-protein
complexes from diabetic hearts [61]. This further
between-study difference may be attributable to differ-
ences in the experimental conditions. However, in our
diabetic animals, the phosphorylation ratio of TnI was
increased (Figure 5i) which may account for their de-
creased myofibrillar Ca2+ sensitivity. TETA treatment
maintained the phosphorylation level of TnI in treated
diabetic animals, therefore contributing to their normal
Ca2+ sensitivity. The altered phosphorylation states of one
or more of the contractile proteins perhaps reflect in-
creased protein kinase C (PKC) activity [71]. This is con-
firmed by our previous report that myocardial PKCδ gene
expression is increased by ~30% in diabetic myocardium
[72]. PKCδ is uniquely able to phosphorylate Ser23/Ser24
in troponin I; and consequently, like protein kinase A
(PKA), it can reduce myofilament Ca2+ sensitivity [73].
We have previously reported that, in this animal model,
the expression of mRNA corresponding to β-myosin
heavy-chain undergoes a ~50% increase in LV tissues,
whereas that of α-myosin heavy chain is decreased to ~35%
of control values [72]. However, TETA treatment had no
significant effect on the expression of either α-myosin
or β-myosin heavy chains in the myocardium of these
(See figure on previous page.)
Figure 7 Quantification of collagen and F-actin. Quantification of collagen and F-actin were based on signal thresholding of matched LV
endocardial areas from each group (n = 7 per group). To avoid possible effects of orientation and origin of the muscle fibres on the
quantification, three transverse optical sections per animal were analyzed. Results have been expressed as percentages of corresponding cross-
sectional areas. (A) A representative image illustrating application of the signal thresholding procedure. Mask1 eliminated the unlabelled area;
mask2 additionally removed the F-actin labelled area. (B) Histogram of representative images from the three experimental groups showing the
thresholds used for quantification. The criteria used for the thresholding process were maintained the same for each of the three experimental
groups. The threshold setup for quantifying F-actin labelling was based on both the original image and the image following application of
mask1. The threshold setup for quantifying collagen labelling was based on both the original image and the image after application of both
mask1 and mask2. Shadowed areas represent signals used for quantification. (C) Results show that diabetic rats had increased type-I collagen
content compared to controls (Diabetic: 7.1 ± 0.1% area; Control: 6.2 ± 0.2% area, P = 0.003), and TETA prevented this increase by retaining normal
values (TETA-treated diabetic: 6.6 ± 0.1% area, P = 0.008). Diabetic rats also developed lowered F-actin content compared to control rats (Diabetic:
56.9 ± 0.6% area; Control: 61.7 ± 0.4% area, P < 0.0001); whereas, TETA-treatment prevented the lowering of F-actin values (TETA-treated diabetic:
60.4 ± 0.5% area, P < 0.0001). Type-III collagen did not differ significantly between groups. Data are means ± SEM, one-way ANOVA with post-hoc
Tukey’s Multiple Comparisons test. * C vs D; † D vs D + T; P < 0.05.
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diabetic animals (Cooper GJ et al., unpubl. data). This
would exclude the contribution of changes in the ex-
pression of myosin isoforms to TETA’s inotropic effect.
Further, we report here that diabetes decreases total
myocardial copper to markedly-lowered values, whereas
we previously showed increases in the systemic and cardiac
Cu(II) in the same diabetic model, as can be extracted by
intra-arterial infusion of TETA. The excess Cu(II) is likely
to be bound in the ECM [23,25] since copper is mainly
(~95%) present in the intracellular compartment as Cu(I)
and the remaining ~5% is in the extracellular space as Cu
(II) [74,75]. While increased extracellular Cu(II) can pro-
mote oxidative stress by generating hydroxyl radicals [8],
decreased myocardial copper can also act to cause pro-
oxidant stress by impairing antioxidant defences mediated
by copper-enzymes, for example lowered activity of endo-
thelial EC-SOD and plasma ferroxidase [25,29,76]. These
effects are all reversible by TETA-treatment [25,29,76]. In
addition, we have shown at the protein level that TETA
can lower ROS production by reversing the impaired
expression of mitochondrial proteins involved in their pro-
duction in diabetic LV tissue [77]. The increased oxidative
stress in diabetic rats can lead to increased levels of
oxidized-glutathione, further contributing to decreased
Ca2+ sensitivity [78], which is confirmed by our previ-
ous study showing that mRNAs corresponding to sev-
eral enzymes regulating aspects of glutathione metabolism
were altered in diabetic cardiomyopathy [72]. Thus TETA
treatment can bolster antioxidant defences in diabetic ani-
mals [29], thereby contributing to maintenance of myocar-
dial Ca2+ sensitivity.
Myocardial copper deficiency is a known cause of
myocardial fibrosis and cardiac failure [12,13,15,16]. Our
findings suggest that the relative distribution of the two
copper valence states has become dysregulated in dia-
betic cardiomyopathy. While total myocardial Cu level
was decreased in diabetic cardiomyopathy, systemic and
cardiac Cu (II) levels were increased [23,25]. This
phenomenon is different from that in dietary copper
restriction-induced cardiomyopathy, where both myo-
cardial and systemic copper levels are decreased [13,15].
Interestingly, there is a report that, in a heart-specific
knockout of Ctr1, cardiomyopathy induced by lack of
myocardial copper transport led to decreased copper
accumulation in cardiac tissue, accompanied by an unex-
pected increase in serum copper levels [79]. The authors
suggested that peripheral organs may communicate with
copper acquisition and storage organs through an un-
known mechanism. This finding indicates the need for
further studies on copper transport and its regulation in
different organ systems in our diabetic animal models,
to improve understanding of copper regulation in dia-
betes and in association with the response to TETA
treatment.
Consistent with our previous reports [23,32], cardiac
remodelling in diabetic rats was also observed in this
study, as shown by the increased collagen content and
disrupted F-actin in LV tissue (Figures 6, 7). We previ-
ously demonstrated regeneration of cardiac structure by
TETA after cardiomyopathy had been present for several
weeks [23]. By contrast, we show here that TETA
prevented the development of cardiomyopathy and re-
modelling when administered ab initio. The increased
collagen content and disrupted F-actin in diabetic hearts
could in part account for the depressed cardiac contract-
ility and decreased myofibrillar Ca2+ sensitivity observed
therein (Figures 1, 2). TETA significantly prevented
excessive collagen deposition and F-actin disruption,
thereby maintaining muscle integrity in diabetic hearts
(Figures 6, 7), which could account for its prevention
of defective myocardial contractility and Ca2+ sensitiv-
ity. The mechanisms underlying this suppression of
cardiac remodelling may be attributable to the im-
paired activity of endothelial EC-SOD and plasma
ferroxidase in our STZ-diabetic animals. These impair-
ments could cause myocardial fibrosis via excessive
TGF-β/SMAD signaling. However, these effects are re-
versible by TETA-treatment [25,76]. Our previous data
indicate that TETA action may suppress the patho-
genic activation of a myocardial TGF-β/SMAD signal-
ling pathway that in turn mediates the expression of
genes encoding extracellular matrix (ECM) proteins
and ECM-degrading enzymes [80,81], by restoration of
normal EC-SOD regulation.
This study has potential limitations. Some workers
have suggested that the cardiomyopathy in STZ-diabetic
rats may reflect, at least in part, direct myocardial tox-
icity of the drug in addition to the effects of diabetes
per se. However, we have validated the STZ-based model
we used here by showing that these diabetic rats respond
both to untreated diabetes and following TETA treat-
ment, in ways that closely reflect responses in patients
with T2D [21-24,28]. To date, we have shown that TETA
treatment exerts substantive effects to restore LV mass
in patients with LVH [24]. There are large gaps in
current understanding of diabetes-mediated effects on
the molecular regulation of myocardial copper homeo-
stasis, and the molecular basis of its restoration by
TETA treatment. Studies to clarify these issues are
clearly required. Furthermore, there are newly described
mechanisms influencing cardiomyocyte function that
may act in parallel with defective copper regulation. For
instance, Zn2+-mediated effects on myocardial relaxation
are more pronounced in the hyperglycaemic state, pos-
sibly due an insulin-dependent effect in enhancing se-
questration of [Ca2+]i via SERCA2a [63]. The peptide
obestatin, which is encoded by the ghrelin gene, up-
regulates the transcription of myocardial β1-adrenergic
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receptors [82]. Moreover, alpha-lipoic acid diminishes
interstitial fibrosis by decreasing collagen deposition
[83]. These three effects are endogenous in mammals
and may represent potentially confounding mechanisms
when evaluating myocardial function. Whether any of
these other factors will ultimately prove to be of clinical
significance awaits the introduction of interventions
based on these processes into informative clinical trials.
In this study, we have relied upon the high degree
of specificity of Cu2+-TETA binding [25,26], as well as
direct measurements of myocardial copper by PIXE, and
our prior quantitative studies of systemic copper homeo-
stasis, to support the role of copper in the processes
under study. The findings we have reported here are con-
sistent with our recent study showing TETA-mediated
reversal of LV dysfunction in diabetic rats in vivo [28].
However, there are as yet no published data showing that
TETA treatment can suppress overt heart failure in dia-
betic patients. Furthermore, in order to establish the valid-
ity of TETA treatment for this condition, it will be
necessary to show that it has a clinically significant benefi-
cial effect on important outcomes such as mortality and/
or hospitalization. Such data are not yet available.
In conclusion, we report here that TETA-treatment
prevented the development of diabetes-induced cardiac
dysfunction without modifying elevated circulating blood
glucose levels, thereby breaking the link between hyper-
glycaemia and myocardial damage. Our data support the
hypothesis that altered [Ca2+]i handling is unlikely to be
the primary contributor to cardiac dysfunction in dia-
betes. The maintenance of normal cardiac contractility
in TETA-treated diabetic rats may be attributable to
chelator-mediated prevention of deterioration in myofi-
brillar Ca2+ sensitivity and cardiac muscle structure. The
molecular basis of TETA function requires further eluci-
dation. We would note that it is already documented to
repair mitochondrial structure-function, extracellular
matrix integrity and myocardial contractile machinery
via restoration of myocardial copper-catalysed anti-
oxidant defences.
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